Loading
Gastro-oesophageal oncologist who co-led CheckMate 649, the trial that added nivolumab to first-line gastric cancer chemotherapy.
Jaffer Ajani was a lead investigator of CheckMate 649, which showed nivolumab plus chemotherapy improves survival in first-line advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma, and of CheckMate 648 in oesophageal squamous cancer. He chaired the NCCN gastric and oesophageal guideline panels for many years and studies the biology of peritoneal metastasis.
Shares Oesophageal cancer, Nivolumab, PD-1, Gastric & gastro-oesophageal junction cancer and the tags esophageal, immunotherapy.
Shares Oesophageal cancer, Nivolumab, PD-1, Immune checkpoint inhibitors and the tags esophageal, immunotherapy.
Shares CheckMate 649, CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma, Oesophageal cancer, Nivolumab.
Shares MD Anderson Cancer Center, Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.